Anteris Technologies Global Corp AVR

$5.87 -0.13 (-2.17%)

Valuation

Market cap
572,078,000
Revenue TTM
$1,910,000
Net income TTM
$-94,140,000
PE ratio
0.00
Forward PE
—
Profit margin
-4,928.80%
Debt to equity
0.00

Trading

Volume
901,700
Avg volume
1,026,576
Day's range
$5.85 – $6.08
Shares out
97,458,000
Stochastic %K
6%
Beta
1.87
Analysts
Strong Sell
Price target
$14.20

Price

Company profile

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissu...

Show more

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Industry
Medical Devices
Sector
Healthcare
Phone
61 7 3152 3200
Website
https://anteristech.com
Address
Toowong Tower, Level 3, Suite 302 9 Sherwood Road, Toowong, Australia

Latest news

Stocktwits

TitanMoonofSaturn Oct 22, 7:46 PM
$AVR 👀 ripe $EW $MDT $BSX https://tavr-research.org/article/tavr-durability-full-2026
1 replies
Idvst8 Oct 21, 9:59 PM
$AVR - Painful thus far.....and lonely. Sigh...............
1 replies
Idvst8 Oct 21, 3:06 PM
$AVR - Not holding up well. Buying OPP here $6.14........ I'll snag some more
0 replies
Idvst8 Oct 21, 2:19 PM
$AVR - Still a name that nobody is talking about. Enrollment updates in coming Months should at least build awareness. Seems a bit oversold here.
0 replies
Idvst8 Oct 20, 5:54 PM
$AVR - Maybe a very slow road, but this has incredible potential. My plan is to continue to add, and just put it away until 2028
0 replies
Orlandotrader Oct 20, 12:54 PM
$AVR just now got Germany. What has this company been doing over the past year since the Capital Raise . 320 million most likely down 100 Million to around 220 Million. Raise coming by Spring 2027. 5$ incoming.
0 replies
Templar57 Oct 20, 11:21 AM
$AVR “Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the German Federal Institute for Drugs and Medical Devices (BfArM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the “PARADIGM Trial”). This clearance enables Anteris to initiate patient recruitment at leading German centers and represents an important step in expanding the PARADIGM Trial’s European footprint. Germany is Europe’s largest and most established transcatheter aortic valve replacement (TAVR) market.
0 replies
focafoca99 Oct 20, 5:03 AM
$AVR released German regulatory clearance for its DurAVR PARADIGM trial, enabling patient recruitment in Europe.
1 replies